Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction
Kei Kunimasa, Toru Oka, Satoshi Hara, Noriyuki Yamada, Satoshi Oizumi, Yoshihiro Miyashita, Risa Kamada, Tomoya Funamoto, Hayato Kawachi, Takahisa Kawamura, Takako Inoue, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Takashi Matsunaga, Fumio Imamura, Masashi Fujita, Toru Kumagai
Topics & Concepts
OsimertinibMedicineDiscontinuationInternal medicineEjection fractionLung cancerConfidence intervalCancerOncologyHeart failureAdenocarcinomaROS1Lung Cancer Treatments and MutationsChemotherapy-induced cardiotoxicity and mitigationInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis